Interleukin-24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell

Liu, Li; Ma, Jun; Qin, Lanyi; Shi, Xiaogang; Si, Hongqiang; Wei, Yahui

doi:10.1097/md.0000000000015875

Cited by 9 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AML can be transformed into malignant changes of hematopoietic progenitors at different stages of normal myeloid cells ( 1 ). Currently, the treatment of AML mainly includes chemotherapy, biologics, and hematopoietic stem cell transplantation (HSCT) ( 2 ), but about 70% of patients who achieve remission will eventually relapse or evolve into refractory leukemia, leading to treatment failure and death ( 3 ). The prognosis and survival rate of AML prognosis are unsatisfactory, and it has been reported the 5-year overall survival (OS) ratein young AML patients is less than 50%, and the 2-year OS rate in older patients after diagnosis is only 20% ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

Establishment of a risk model correlated with metabolism based on RNA-binding proteins associated with cell pyroptosis in acute myeloid leukemia

et al. 2022

View full text Add to dashboard Cite

BackgroundRNA-binding protein (RBP) regulates acute myeloid leukemia (AML) by participating in mRNA editing and modification. Pyroptosis also plays an immunomodulatory function in AML. Therefore, this study aimed to identify pyroptosis-related RBP genes that could predict the prognosis of AML patients.MethodsAML related expression data were downloaded from the UCSC website and Gene Expression Omnibus (GEO) database. Pyroptosis-RPB-related differentially expressed genes (PRBP-DEGs) were conducted with a protein-protein interactions (PPI) network to screen out the key PRBP-DEGs, based on which a risk model was constructed by Cox analysis, and evaluated by plotting Receiver operating characteristic (ROC) curves and survival curves. Independent prognostic analysis was performed and a nomogram was constructed. Finally, enrichment analysis was performed for high and low risk groups.ReusltsA total of 71 PRBP-DEGs were obtained and a pyroptosis-RPB-related risk model was constructed based on IFIT5, MRPL14, MRPL21, MRPL39, MVP, and PUSL1 acquired from Cox analysis. RiskScore, age, and cytogenetics risk category were identified as independent prognostic factors, and the nomogram based on these independent prognostic factors could accurately predict 1-, 3- and 5-year survival of AML patients. Gene set enrichment analysis (GSEA) showed that the high-risk and low-risk groups were mainly enriched in metabolic- and immune-related processes and pathways.ConclusionIn this study, a risk score model correlated with metabolism based on RNA-binding proteins associated with cell pyroptosis in acute myeloid leukemia was established, which provided a theoretical basis and reference value for therapeutic studies and prognosis of AML.

show abstract

Section: Introductionmentioning

confidence: 99%

Establishment of a risk model correlated with metabolism based on RNA-binding proteins associated with cell pyroptosis in acute myeloid leukemia

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A recent trial found regulated expression of recombinant IL-12, following intratumoral injection of Ad-RTS-hIL-12 in combination with oral veledimex, to be safe in 31 patients with recurrent glioblastoma [42]. In addition to IL-12, several other interleukins, including IL-2, IL-24 and IL-13, have been used to arm oncolytic adenovirus and have shown promising immune-activating properties in multiple preclinical cancer models [43][44][45].…”

Section: Immunostimulatory Molecules-expressing Adenovirus Vectorsmentioning

confidence: 99%

Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination

Sato-Dahlman

LaRocca

Yanagiba

et al. 2020

Cancers

View full text Add to dashboard Cite

Gene therapy with viral vectors has significantly advanced in the past few decades, with adenovirus being one of the most commonly employed vectors for cancer gene therapy. Adenovirus vectors can be divided into 2 groups: (1) replication-deficient viruses; and (2) replication-competent, oncolytic (OVs) viruses. Replication-deficient adenoviruses have been explored as vaccine carriers and gene therapy vectors. Oncolytic adenoviruses are designed to selectively target, replicate, and directly destroy cancer cells. Additionally, virus-mediated cell lysis releases tumor antigens and induces local inflammation (e.g., immunogenic cell death), which contributes significantly to the reversal of local immune suppression and development of antitumor immune responses (“cold” tumor into “hot” tumor). There is a growing body of evidence suggesting that the host immune response may provide a critical boost for the efficacy of oncolytic virotherapy. Additionally, genetic engineering of oncolytic viruses allows local expression of immune therapeutics, thereby reducing related toxicities. Therefore, the combination of oncolytic virus and immunotherapy is an attractive therapeutic strategy for cancer treatment. In this review, we focus on adenovirus-based vectors and discuss recent progress in combination therapy of adenoviruses with immunotherapy in preclinical and clinical studies.

show abstract

“…[1]. A variety of chemotherapy regimens, biological agents, and stem cell transplantation are the main treatment options for AML [2][3][4]. However, chemotherapy drug toxicity may lead to acute and life-threatening complications.…”

Section: Introductionmentioning

confidence: 99%

Comprehensive Gene Expression Analysis Reveals Factors that Influence the Progression, Occurrence and Development of AML-M4

Zhang

et al. 2019

Preprint

View full text Add to dashboard Cite

Background Acute myelomonocytic leukemia (M4), a special type of acute myeloid leukemia (AML), is a clonal malignant disease with poor prognosis and a low overall survival rate. Here, we aim to explore the molecular mechanism of AML-M4 development and progression using integrative bioinformatic analysis. Methods We used an integrative method to identify potential driven genes in AML-M4. We firstly identify DEGs using limma packages and annotated them by GO and KEGG. To avoid individual bias, GSEA was adopted to certify the results. Furthermore, we constructed the PPI network using WGCNA which was superimposed onto STRING database. We also assessed the correlation and mutation among hub genes to deeply explore the biological mechanism in AML-M4. Finally, we confirmed our results by experiments. Results The results show that FLT3, WT1 and TP53, which are involved in transcriptional misregulation were upregulated, while PPBP and CCR7, which regulate cytokine-cytokine receptor interaction, as well as CD24, which acts as a protein marker of AML, were downregulated. 12 hub genes were found through the TCGA an Oncomain analysis, and the results also show that FLT3, CCR7 and MMP-9 can be potential targets for the detection and treatment of AML-M4. Conclusion The overall aim of this study was to identify critical pathways and genes associated with AML-M4, and to also provide potential therapeutic targets and new research ideas for the treatment and early detection of AML-M4.

show abstract

Interleukin-24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell

Cited by 9 publications

References 31 publications

Establishment of a risk model correlated with metabolism based on RNA-binding proteins associated with cell pyroptosis in acute myeloid leukemia

Establishment of a risk model correlated with metabolism based on RNA-binding proteins associated with cell pyroptosis in acute myeloid leukemia

Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination

Comprehensive Gene Expression Analysis Reveals Factors that Influence the Progression, Occurrence and Development of AML-M4

Contact Info

Product

Resources

About